Five commercially available enzyme-linked immunosorbent assays (ELISAs), one in-house ELISA, and two hemagglutination assays were evaluated to determine their diagnostic accuracy for Chagas' disease in two studies. In study 1, ELISA kits showed 100% sensitivity, but specificities ranged from 82.84% to 100% when leishmaniasis cases were included and from 95.57% to 100% when leishmaniasis cases were excluded. Kits using recombinant antigens or synthetic peptides are more specific than those using crude extracts from Trypanosoma cruzi epimastigote forms. Kits evaluated in Panama, in study 2, showed 75% to 100% sensitivity and 97.12% to 100% specificity. These data were obtained by using a Western blot assay with T. cruzi trypomastigote excreted-secreted antigens as a reference test to confirm T. cruzi infection.
doubtful depending on the commercial diagnostic assay used for blood screening (5, 6, 7) . The definition of inconclusive results differs with the commercial kit used, since reactions that are not clearly positive or negative are taken as inconclusive. Currently available kits are very effective at detecting blood donors presenting with high anti-T. cruzi antibody titers, but the results are often questionable when the kits are used for donors with low titers (7, 18) . For the latter donors, it is not uncommon for a sample to be negative by one test when subjected to two or three tests (8) . Some of these samples are known to be from genuine Chagas' disease patients, because they are confirmed by molecular biology methods (PCR) (7); other researchers have reported evidence that people infected with T. cruzi can have negative serology (16, 23) .
Another factor that needs to be taken into consideration when one is using serological tests for Chagas' disease is crossreactivity. Cross-reactivity between sera of patients infected with T. cruzi and sera of patients infected with Leishmania spp. in the serodiagnosis of Chagas' disease is well documented (2, 20) . In some areas of endemicity in Central America and Brazil, where T. cruzi and the nonpathogenic protozoan Trypanosoma rangeli can be found infecting the same vectors and vertebrate hosts (12, 14) , cross-reactivity has been the subject of discussion.
The aim of our study, which was divided into two separate studies (studies 1 and 2), was to compare the sensitivities and specificities of nine Chagas' disease assays for detection of anti-T. cruzi immunoglobulin G: six enzyme-linked immunosorbent assays (ELISAs), two IHAs, and one Western blot assay. Of these tests, the following seven are commercially available: three ELISAs manufactured with T. cruzi epimastigote antigens ( (20) . The TESA blot was used as a reference test (20, 21, 23) . All commercial kits were used according to the manufacturers' instructions, and the test results were analyzed in accordance with the technical information provided for each assay. The cutoffs were calculated as described in the respective sections of each manual. For ELISA-IMT, the cutoff was calculated as the mean optical density (OD) at 492 nm of the true-negative sera plus 3 standard deviations. The individual results were calculated as the ratio of the OD to the cutoff (see Fig. 1 ). A sample was considered positive if the ratio was equal to or greater than 1.0 and negative if the ratio was equal to or smaller than 0.99. Seropositivity rates for anti-T. cruzi antibodies in different tests, and their confidence intervals [CIs], were calculated using the mid-P 95% confidence interval (95% CI) using Epi Info (version 6.0) software (see Table 2 ). Samples that yielded discrepant results were tested at least twice on different days.
The guidelines of the Standards for Reporting of Diagnostic Accuracy were applied in this study.
In study 1, all ELISAs and the TESA blot had a sensitivity of 100% (95% CI, 94.5 to 100%) when evaluated with 53 samples collected from Brazilian blood donors with T. cruzi infection (18 to 60 years old; 60% male, 40% female) who had previ- Table 1 ). Patients infected with T. rangeli or Leishmania spp. were selected using epidemiological, clinical, and/or parasitological data (data not shown).
In study 1, the specificities (95% CIs) of EIAs prepared with T. cruzi epimastigote antigens, including results for Leishmania sp. cases, were as follows: for ELISA-IMT, 85.07% (78.3 to 90.4%); for Chagas III, 90.30% (84.3 to 94.5%); for ELISAcruzi, 82.84% (75.7 to 88.5%); and for Chagatek, 87.31% (80.9 to 92.2%) ( Table 2 ; Fig. 1) . A specificity of 100% (97.8 to 100%) was achieved with EIAs prepared with recombinant T. cruzi antigens (Chagatest Rec v3.0 and Pathozyme) ( Table 2) . When leishmaniasis cases (n ϭ 21) were excluded, the specificities of the kits (95.57 to 100%) indicated improved diagnostic performance (Table 2) . No cross-reactivity with the 23 T. rangeli cases was observed in the ELISAs or the TESA blot, except for the ELISA-IMT, which cross-reacted with two cases (8.69%). These two patients had low titers (Table 1 ; Fig. 1, Tr) . VOL. 14, 2007 14, NOTES 1047 No cross-reactivity was observed with samples from T. rangeli or Leishmania sp. cases or from cases with other infections by using the TESA blot (Table 1) . However, 2.24% (3/ 134) of the samples (1 from a healthy individual, 1 from an individual infected with Leishmania spp., and 1 from an individual infected with T. rangeli) reacted, resulting in a faint band of 170 kDa in the TESA blot; this band can be confused with the 150-to 160-kDa band that is evident with sera of T. cruziinfected individuals (data not shown).
Individuals infected with T. rangeli appear not to produce T. cruzi-or T. rangeli-reactive antibodies; they failed to show reactivity in an ELISA prepared with T. rangeli extracts (data not shown). These results, which agree with the findings of other studies, show that human infection with T. rangeli does not cause the production of enough cross-reacting antibodies to interfere with the serodiagnosis of Chagas' disease (13, 14) . However, this does not exclude the possibility that exposure to T. rangeli may elicit a particular humoral and/or cellular immune response that confers some degree of protection against subsequent infection with T. cruzi (11) .
The next step, in study 2, was to validate these assays by a retrospective study with 120 samples from individuals, aged 18 to 60 years, living in an area of endemicity in Mendoza, Panama. According to an earlier study, 2.91% and 6.80% of the children in this area are infected with T. cruzi and T. rangeli, respectively (13) . In study 2, Chagas III gave positive results for 13.33% (n ϭ 16) of the samples. ELISA-IMT, ELISAcruzi, and Chagatek gave a positivity rate of 15% (n ϭ 18). Positivity rates for Chagatest Rec v3.0 and Pathozyme were 10.83% (n ϭ 13) and 10% (n ϭ 12), respectively ( Table 1 ). The sensitivity, calculated using the TESA blot as a reference test, was 100% (82.9 to 100.0%) for the ELISA-IMT and Chagatek tests. The same result was not observed for the other tests; Chagas III and ELISAcruzi had a sensitivity of 93.75% (72.8 to 99.7%), Chagatest Rec v3.0 had 81.25% (57.0 to 95.0%), and Pathozyme had 75% (50.1 to 91.5%) ( Table 2 ; Fig. 1 Tables  1 and 2 ).
In summary, our data, and those from other laboratories, indicate that commercial kits that use recombinant antigens or synthetic peptides are a more specific alternative to those that use complex crude extracts, although they sometimes have variable sensitivities (18, 21) . Confirmatory tests with higher specificities have already been proposed as reference standards (3, 4, 20, 21, 23) , but unfortunately none of these are commercially available.
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